The purpose of this research study is to see how well an imaging test, called 18FDCFPyL prostate specific membrane antigen (PSMA) positron emission tomography (PET), can show the extent of prostate cancer when comparing to 68Ga-PSMA-11 PET/CT (another type of diagnostic scan for prostate cancer).
Participants must have histologically or cytologically confirmed prostate cancer.
Age ≥18 years.
Participants must be planned for standard-of-care 177Lu-Vipivotide Tetraxetan therapy after the 18F-DCFPyL PSMA-PET.
Ability and willingness to comply with the study procedures.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
Contraindications to PET/CT, including severe claustrophobia.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to 18F-DCFPyL
Any past or current condition that, in the opinion of the study investigators, would confound the results of the study or would pose additional risk or burden to the patient by their participation in the study.
Single group
18F-DCFPyl
DrugFluorine-labeled small molecule, via intravenous infusion per protocol.
Proportion of Participants with PSMA-Positive Lesion
Defined as the number of participants with at least 1 PSMA-positive lesion on 18F-DCFPyL PSMA-PET.
Click on the lead sponsor to view all of their trials.
Brigham and Women's Hospital
Lead sponsor
Progenics Pharmaceuticals, Inc.
Collaborator
